LL-37 vs Thymulin
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: Cathelicidin, CAP18
LL-37 is the only cathelicidin antimicrobial peptide humans make, a 37-amino-acid, positively charged, helical fragment cut from a precursor protein called hCAP-18. It is a frontline player in the innate immune system, part of the body's chemical defense against bacteria, viruses, and fungi. This is mainstream, heavily studied human biology, not a fringe research peptide, though LL-37 itself is not an approved drug.
Also: Facteur thymique serique, FTS
Thymulin is a tiny nine-amino-acid hormone made by the epithelial cells of the thymus, first described in the 1970s as facteur thymique serique (FTS). It only works when bound to one zinc atom, which makes it an oddly neat marker of zinc status. It plays a part in training T cells, and animal work suggests anti-inflammatory and pain-reducing effects. It is sold online for immune support and hair loss, but there are no modern human trials of giving it, and the hair claims rest on lab dishes and a sponsor-linked cosmetic study.
Key Comparison Insights
- Both peptides belong to the Immune category, suggesting similar primary applications.
- LL-37 has stronger research evidence (Human Trials) compared to Thymulin (Preclinical).
Detailed Comparison
| Attribute | LL-37 | Thymulin |
|---|---|---|
| Category | Immune | Immune |
| FDA Status | Not FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | LL-37 carries a net positive charge and has a water-loving and fat-loving (amphipathic) structure, which lets it home in on the negatively charged membranes of bacteria and physically punch holes in them. But killing microbes directly is only half the job. It also acts as a signaling molecule: it neutralizes bacterial toxin LPS, calms or tunes the inflammatory response, recruits immune cells to wounds and infection sites, and helps skin re-grow and close over injuries. It is produced by skin, gut, lung, and other epithelial cells, plus immune cells like neutrophils. This dual role, direct antimicrobial plus immune coordinator, is why it is described as a multifunctional host-defense peptide. | Thymulin (sequence Glu-Ala-Lys-Ser-Gln-Gly-Gly-Ser-Asn) binds zinc in a 1:1 ratio, and only the zinc-bound form has biological activity. It promotes T cell differentiation inside and outside the thymus and influences T cell subsets and cytokine production. Its levels fall with age as the thymus shrinks, and fall with zinc deficiency. Researchers led by Goya and Reggiani have described a two-way link with the pituitary: thymulin seems to affect pituitary hormone release, and pituitary hormones affect thymulin secretion. In rodent models, thymulin and a synthetic analogue reduced inflammation and pain signalling, partly by dampening pro-inflammatory cytokines. How much of this applies to a peptide injected into a healthy adult is unknown. |
| Common Dosing | 100-200 mcg daily Once daily | No established dose Unknown |
| Administration | Subcutaneous injection or topical | Sold for subcutaneous injection or topical use; neither route has been tested in controlled human trials |
| Typical Duration | Variable by protocol | Unknown; no human trials to guide duration |
| Best Time to Take | Morning | No evidence-based timing |
Possible Side Effects May vary by individual |
|
|
| Research Summary | The basic biology of LL-37 is well established across many peer-reviewed studies. Its broad antimicrobial activity, membrane-disrupting mechanism, and tissue distribution are documented in reviews such as those in the Journal of Leukocyte Biology and PMC-indexed updates on how it limits the spread of local infection. Research has also explored more speculative directions: LL-37 and engineered mimics have shown anticancer activity in laboratory models, and it has been studied as a possible host-defense factor against Helicobacter pylori in the stomach and against pathogens on the surface of the eye. The important honesty point is that almost all of this is mechanistic and preclinical. LL-37 is firmly proven as a natural part of human immunity, but as a deliberately administered therapy it has not cleared large human clinical trials, and its dual nature means it can also drive inflammation in some disease states. So: rock-solid as biology, still experimental as a treatment. | Most of what is solid here is basic physiology. Dardenne and Pleau (1994) reviewed the zinc dependence: no zinc, no activity. Prasad and colleagues (JCI, 1988) showed that serum thymulin activity dropped in people made mildly zinc deficient by diet and came back with zinc supplementation, alongside shifts in T cell ratios and IL-2, so thymulin is a useful readout of zinc status. Reviews by Reggiani, Goya and colleagues (2012-2014) summarize anti-inflammatory and analgesic effects in rodents and gene therapy work in athymic mice, but frame human use as a future goal. On hair: Meier and colleagues (J Invest Dermatol, 2012) found a low dose of thymulin increased hair shaft growth in organ-cultured human scalp follicles, a dish result rather than a clinical one. A 2013 cosmetic study of a thymus peptide serum and shampoo reported less hair shedding on pull tests, but it was tied to the product maker and not a controlled regrowth trial. There are no controlled trials of injected or topical thymulin for immunity, aging or hair in people, and no human safety data. If you have low zinc, fixing that is better proven than adding the peptide. |
Frequently Asked Questions: LL-37 vs Thymulin
What is the difference between LL-37 and Thymulin?
LL-37 is a immune peptide that ll-37 is the only cathelicidin antimicrobial peptide humans make, a 37-amino-acid, positively charged, helical fragment cut from a precursor protein called hcap-18. it is a frontline player in the innate immune system, part of the body's chemical defense against bacteria, viruses, and fungi. this is mainstream, heavily studied human biology, not a fringe research peptide, though ll-37 itself is not an approved drug. Thymulin is a immune peptide that thymulin is a tiny nine-amino-acid hormone made by the epithelial cells of the thymus, first described in the 1970s as facteur thymique serique (fts). it only works when bound to one zinc atom, which makes it an oddly neat marker of zinc status. it plays a part in training t cells, and animal work suggests anti-inflammatory and pain-reducing effects. it is sold online for immune support and hair loss, but there are no modern human trials of giving it, and the hair claims rest on lab dishes and a sponsor-linked cosmetic study. The main differences lie in their mechanisms of action and clinical applications.
Which is better, LL-37 or Thymulin?
Neither is universally "better" - the choice depends on your specific goals. LL-37 is typically used for immune purposes, while Thymulin is used for immune. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can LL-37 and Thymulin be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using LL-37 and Thymulin together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.